Hostname: page-component-848d4c4894-hfldf Total loading time: 0 Render date: 2024-05-30T21:27:22.662Z Has data issue: false hasContentIssue false
  • English
  • Français

Hepatitis B Vaccine: Persistence of Antibody Following Immunization

Published online by Cambridge University Press:  21 June 2016

Gary P. Barnas  and
Linda J. Hanacik
Gary P. Barnas*
Affiliation:
Division of General Internal Medicine, Medical College of Wisconsin, and the Infection Control Department, Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin
Linda J. Hanacik
Affiliation:
Division of General Internal Medicine, Medical College of Wisconsin, and the Infection Control Department, Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin
*
Milwaukee County Medical Complex, Box 135, 8700 W. Wisconsin Ave., Milwaukee, WI 53226
Get access Rights & Permissions [Opens in a new window]

Abstract

We examined the persistence of hepatitis B surface antibody following hepatitis B vaccination in a group of health care workers. Of the 187 vaccine recipients screened, 39 were found to be antibody negative. Life table analysis showed the proportion retaining antibody at one, two, three, and four years from the first dose of vaccine was 92%, 84%, 73%, and 55% respectively. The likelihood of retaining antibody was significantly decreased as the age of the vaccine recipient increased. These results indicate that a large proportion of vaccine recipients no longer had detectable antibody four years after receipt of the vaccine. It remains to be shown if such individuals who have lost antibody are susceptible to the development of clinical hepatitis.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 9 , Issue 4 , April 1988 , pp. 147 - 150
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1988

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Centers for Disease Control, Immunization Practice Advisory Committee: Recommendation for protection against viral hepatitis. MMWR 1985; 34:313–335.Google Scholar
2. Szmuness, W, Stevens, CE, Zang, E 4, et al: A controlled clinical trial of the efficacy of the hepatitir B vaccine (Heptavax B): A final report. Hepatology 1981; 1:377–385.CrossRefGoogle ScholarPubMed
3. Szmuness, W, Stevens, CE, EJ, Harley, et al: Hepatitis B vaccine in medical staff of hemodialysis units. Efficacy and subtype cross-protection. N Engl J Med 1982; 307:1481–1486.10.1056/NEJM198212093072403CrossRefGoogle ScholarPubMed
4. Francis, DP, SC, Hadler, Thompson, SE, et al: The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982; 97:302–366.10.7326/0003-4819-97-3-362CrossRefGoogle ScholarPubMed
5. Centers for Disease Control: Hepatitis B virus vaccine safety: Report of an interagency group. MMWR 1982; 31:465–467.Google Scholar
6. Francis, DP, PM, Feorno, McDougal, S, et al: The safety of the hepatitis B vaccine. Inactivation of the AIDS virus during routine vaccine manufacture. JAMA 1986: 236:869–872.CrossRefGoogle Scholar
7. JD, Hamilton: Hepatitis B virus vaccine. An analysis of us potential use in medical workers. JAMA 1983; 250:2145–2150.Google Scholar
8. Mulley, AG, MD, Silverstein, JL, Dienstag: Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. N Engl J Med 1982; 307:644–652.CrossRefGoogle ScholarPubMed
9. Tong, MJ, AM, Howard, GC, Schatr, et al: A hepatitis B vaccination program in a community teaching hospital. Infect Control 1987; 8: 102–107.CrossRefGoogle Scholar
10. Dienstag, JL, BG, Werner, Polk, BF, et al: Hepatitis B vaccine m health care personnel: Safety, immunogenicity, and indicators of efficacy. Ann Inlern Med 1984; 101:34–40.CrossRefGoogle Scholar
1 I. MW, Humble, PA, Maddocks: Experience with full-dosr hepatitis vaccine in Wellington Hospital staff. NZ Med J 1985; 98:479–481.Google Scholar
12. Krugman, S, Holley, HP, Davidson, M, et al: Immunogenic effect of inactivated hepatitis B vaccine: Comparison of 20 meg and 10 meg doses. J Med Virol 1981; 8:119–121.CrossRefGoogle Scholar
13. Jilg, W, Schmidt, M, F, Deinhardt, et al: Hepatitis B vaccination: How long does protection last? Lancet 1984; 2:458.CrossRefGoogle ScholarPubMed
14. SC, Hadler. Francis, DP, JE, Maynard, et al: Long-term immunogenicity and efficacy of hepatitis B **vaccine in homosexual men. N Engl J Med 1986; 315:209–214.Google Scholar
15. Hanacik, LJ, Franson, TR, JD, Gollup, et al: Implementing a successful hepatitis B vaccination program. Infect Control 1985; 6:306–309.10.1017/S0195941700063153CrossRefGoogle ScholarPubMed
16. Centers for Disease Control: Update on hepatitis B prevention. MMWR 1987; 36:353–366.Google Scholar
17. Coursaget, P, Chotard, J, Vincelot, P, et al: Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet 1986; 2:1143–1145.CrossRefGoogle Scholar
18. Colton, T: Longitudinal studies and use of the life table, in Statistics in Medicine. Boston, Little, Brown and Co., 1974, pp 241–247.Google Scholar
19. Craven, DE, ZL, Awdeh, Kunches, LM, et al: Nonresponsiveness to hepatitis B vaccine in health care workers: Results of revaecinations and genetic typings. Ann Intern Med 1986; 105:356–360.CrossRefGoogle ScholarPubMed
20. Lemon, SM, DJ, Weber: Immunogenicity of plasma-derived hepatitis B vaccine: Relationship to site of injection and obesity. J Gen Intern Med 1986; 1:199–201.10.1007/BF02602339CrossRefGoogle ScholarPubMed
21. Centers for Disease Control: Suboptimal response to hepatitis B vaccine given by injection into the buttock. MMWR 1985: 34:105–113.Google Scholar
22. KD, Miller. Gibbs, RD, MM, Mulligan, et al: Intradermal hepatitis B vaccine: Immunogenicity and side-effects in adults. Lancet 1983; 2:1454–1456.Google Scholar
23. RR, Redfield. BL, Innis. KM, Scott. et al: Clinical evaluation of low-dose intradermaly administered hepatitis B virus vaccine; A cost reduction strategy. JAMA 1985; 254:3203–3206.Google Scholar